Feedback / Questions
Dupixent (dupilumab) - Sanofi, Regeneron
eblasakimab (ASLAN004) - ASLAN Pharma
https://www.globenewswire.com/news-release/2022/09/14/2515833/0/en/ASLAN-Pharmaceuticals-Commences-Clinical-Program-to-Study-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
Sep 14, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next